Notes to the Financial Statements Our Current Performance Note 1: Segment Information The Group’s segments represent strategic business units that offer different products and operate in different industries and markets. They are presented consistent with the way the CEO who is the chief operating decision-maker (CODM) monitors and assesses business performance to make resource allocation decisions. The acquisition of CSL Vifor in August 2022, resulted in a change in which the business is monitored and assessed. The operating segments are now being measured based on the segment operating result, being the revenues and costs directly under the control of the business unit. The Group’s operating segments are: CSL Behring – manufactures, markets and distributes plasma products, gene therapies and recombinants. CSL Seqirus – manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. CSL Vifor – manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. The Group’s centralised research and development (‘R&D’) function builds on its capabilities across the R&D value chain. The Group continues to make balanced investments in life cycle management and market development of existing and new products. Costs related to R&D are reported separately and are not allocated to the operating segments. The Group utilises globally integrated functions to realise economies of scale. The functions include executive office, communications, finance, human resources, legal, information & technology. The costs related to these functions, as well as any other non-business unit related costs (including depreciation and amortisation of unallocated assets) are reported as General and Administration expenses and are not allocated to the operating segments. To enable a comparison of prior year performance, ‘Segment revenue and expenses’ has been restated using the new segments for the prior year comparatives ended 30 June 2022. Segment information is presented as reviewed by the CODM on a regular basis, being the underlying performance of the businesses. A reconciliation of the segment results to the AASB financials is provided within this note. CSL Limited Annual Report 2022/23 118
RkJQdWJsaXNoZXIy MjE2NDg3